Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm…
ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients Glasmacinal, a novel macrolide, was well…
MUMBAI, India, Dec. 4, 2025 /PRNewswire/ -- Tata Communications, a leading global communications technology player, today announced that it has…
MUMBAI, India and DUBAI, UAE, Dec. 3, 2025 /PRNewswire/ -- Spectrum Networks announced it has been named a finalist of the…
The awards-winning robotics company officially kicks off its pre-order window ahead of its main launch at CES 2026.SINGAPORE, Dec. 6,…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
BEIJING, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative…
Launches AI-Powered Agents on Microsoft 365 to Enable Smarter, Seamless Skill-Based Workforce TransformationMUMBAI, India, Dec. 5, 2025 /PRNewswire/ -- Prismforce,…